Sumitomo Pharma Co.Ltd. 4506

Asian stock markets turned in a choppy Thursday, as traders weighed easing petroleum prices but also

By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations. Dr. Koblan is a biopharmaceutical R&D leader with more than 30 years […] The post Slate Medicines Names Kenneth Koblan as Chief Scientific Officer appeared first on ExecEdge.

Nuvisertib targets unmet needs in relapsed/refractory myelofibrosis with differentiated, potentially disease-modifying activity. Combination therapy, expansion into other cancers and expedited regulatory pathways offer additional opportunities.Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Nuvisertib Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Nuvisertib (TP-3654) is an investigational, orally administered, highly selective PIM1 kinase i

Sumitomo Pharma stock has delivered a very large 3 year gain but the broader valuation checks still suggest the shares trade on the cheap side compared with the fundamentals. After a weak year to date performance, the recent rebound raises the question of whether the stock still prices in too much caution or if expectations are finally catching up. Over the past 3 years, Sumitomo Pharma is up about 228.5% which signals a major re rating by the market over that window. The key support for the...

Asian stock markets fell back Wednesday on overnight Wall Street cues, and as traders cooled on tech

Recently published Non-Metastatic Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-metastatic prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

MARLBOROUGH, Mass., August 12, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced that the first patient in its study evaluating DSP-3077 in the treatment of non-syndromic retinitis pigmentosa (RP) has undergone subretinal implantation. DSP-3077 is an investigative regenerative cell therapy that leverages allogeneic retinal sheets derived from induced pluripotent stem (iPS) cells.

Sumitomo Chemical Co Ltd (SOMMF) reports a significant year-on-year profit increase, with improved DE ratio and robust growth in Essential and Green Materials and Agro and Life Solutions segments.

LYON, France, July 30, 2026--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today publishes its revenue figures for the second quarter ended 30 June 2026.

MARLBOROUGH, Mass., July 30, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to enzomenib (DSP-5336) for the treatment of patients with acute lymphoblastic leukemia (ALL). Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase 2A (KMT2A) protein interaction, a key interaction in acute leukemia and other tumor cell proliferation and growth

MARLBOROUGH, Mass., June 15, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced the presentation of new clinical and translational research at the European Hematology Association (EHA) 2026 Congress, held from June 11-14, 2026, in Stockholm, Sweden.

MARLBOROUGH, Mass., June 10, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for enzomenib, an investigational, oral selective menin inhibitor for the treatment of relapsed/refractory acute leukemia with KMT2A rearrangement, to allow for interim analysis. Achieving this milestone will enable SMPA to obtain results of the interim analysis by the end of calendar year 2026. These results wil

Recently published Generalized Anxiety Disorder Market Insights report includes a comprehensive understanding of current treatment practices, generalized anxiety disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

MARLBOROUGH, Mass., June 01, 2026--Sumitomo Pharma America, Inc. (SMPA) today announced clinical data from its ongoing first-in-human Phase 1/2 trial of SMP-3124LP (NCT06526819). SMP-3124LP is a structurally distinct, investigational, selective checkpoint kinase 1 (CHK1) inhibitor delivered via a PEGylated liposome formulation. Designed with the specific goal of treating malignancies characterized by high replication stress, these findings were presented as a poster at the 2026 American Society

Japan's regenerative medicine market offers opportunities driven by an aging population, progressive regulations, and demand for novel therapies targeting chronic and cosmetic conditions. Innovations in stem cell and gene-editing technologies, alongside robust R&D investments and clinical collaborations, further bolster growth potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Japan Regenerative Medicine Market - Distribution by Type of Product, Type of Therapeutic Area, End User and Key Ge

What recent performance says about Sumitomo Pharma shares Sumitomo Pharma (TSE:4506) has drawn attention after a mixed stretch, with the stock up about 84% over the past year but showing declines over the past month and past 3 months. See our latest analysis for Sumitomo Pharma. At a share price of ¥1,729.5, recent trading has shifted from last year’s strong 1 year total shareholder return of 83.79% to weaker short term momentum, with a 30 day share price return showing a decline of 14.47%...

Asian stock markets swung from rally to retreat on Thursday, after US President Donald Trump indicat